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Abstract
Background: Pituitary adenylate cyclase-activating polypeptide (PACAP) is widely distributed in the nervous system and
is involved in migraine pathophysiology. Understanding the function of the blood-brain barrier (BBB) in relation to PACAP
is important to the understand the mechanisms behind PACAP-induced migraine attacks, but also to develop
antimigraine drugs targeting the PACAP receptors Here, we aim to review the transport ability of PACAP across the BBB.
Methods: We performed a systematic literature search on PubMed to identify studies reporting original data on PACAP
and BBB. The search was finalized in July 2017.
Results: The literature search identified 96 papers of which 11 contained relevant data. In addition, two papers were
known to be relevant and were included. A total of 13 papers studies were included in the final analysis. Preclinical
studies (n= 10) suggest the existence of specific PACAP transport systems across the BBB, while human PACAP studies
failed to show vasodilator effect of PACAP on the cerebral arteries from the lumen (n = 3).
Conclusion: PACAP38 is transported over the BBB actively, while PACAP27 cross the BBB by diffusion over the
membrane, but after crossing the endothelial membrane both isoforms are either rapidly degraded or efflux
back from brain to blood. Thus, a direct central action of the PACAPs is unlikely. This is supported by studies
showing selective PACAP effect on extra-cerebral arteries.
Keywords: Migraine, PACAP, Blood-brain barrier
Review
The peptide pituitary adenylate cyclase-activating poly-
peptide (PACAP) is widely distributed in the nervous
system and is found in two major isoforms, PACAP38
and PACAP27, which exert various effects via activation
of the VPAC1, VPAC2 and PAC1 receptors [1]. A grow-
ing body of evidence suggests that PACAP plays an
important role in migraine pathogenesis. For example,
intravenous infusion of PACAP38 provokes migraine
attacks in migraine patients without aura [2, 3] and
induces a marked sustained dilation of extra-cerebral
but not intracerebral arteries in both healthy volunteers
[4] and migraine patients [5]. The exact mechanisms of
PACAP38 induced migraine are unknown. However,
given the abundant distribution of PACAP in the CNS
[6], central pain mechanisms caused by exogenous
PACAP infusion could hypothetically be important.
This raises the important question to which degree
PACAP may cross the blood-brain barrier (BBB). Pre-
clinical studies have reported an active transport system
of PACAP38 across the BBB in the rat [7]. However,
investigations of rat and human cerebral arteries in
vitro, showed that PACAP38 only had effect after
abluminal but not luminal application [8]. Understand-
ing the function of the BBB in relation to PACAP is im-
portant to the understand the mechanisms behind
PACAP-induced migraine attacks triggering, but also to
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develop antimigraine drugs targeting the PACAP recep-
tors [9]. Here, we aimed to present a systematic review
on studies investigating the transport of PACAP across
the BBB.
Methods and materials
We performed a systematic literature search in July
2017 via PubMed to identify studies reporting original
data on PACAP in relation to the BBB. The following
search terms were used: pituitary adenylate cyclase
activating polypeptide or PACAP and blood brain bar-
rier or BBB. No filters were used in the search. Only
studies reporting original data published in English-
written peer-reviewed journals were included. The
first author assessed all titles and abstracts to identify
articles containing relevant data. Subsequently, the
entire articles were read and additional studies known
to be relevant were also included.
Results
Our search strategy resulted in 96 hits out of which 11
studies were included in the final review. In addition,
two studies known to be relevant by the authors were
also included ending up with a total of 13 studies
(Tables 1 and 2). Two out of 13 studies exclusively ex-
amined human arteries [4, 5], while one study reported
data on rat and human arteries [8]. The remaining ten
studies investigated mice [10–18] or rat models [19].
Only one of the studies were performed as migraine
models [5].
Discussion
The main finding in this review is that PACAP can
cross the BBB in both directions (i.e. from blood to
brain and from brain to blood). Preclinical studies
carried out in mice or rats consistently report that
PACAP38 is transported actively from the blood to the
brain (influx) and from the brain to blood (efflux) by
the protein transport system-6 (PTS-6), which is
located in the endothelium. In contrast, studies investi-
gating effect of PACAP38 on the cerebral arteries (i.e.
middle cerebral artery [MCA]) suggest that PACAP38
is not able to cross the endothelium in sufficient
amount to activate receptors in the smooth muscle cells
in the arterial walls [4, 5, 8], which will be discussed in
the following. Historically, the BBB was considered as a
structural barrier between the blood and brain consist-
ing of capillary endothelial cells glued together with
tight junctions and surrounded by glial cell projections.
We now know that the BBB is a functional rather than
just a solid structural barrier, allowing passage in from
blood to brain and from brain to blood via different
mechanisms. Peptides that cross the BBB are either
actively transported by saturable carrier- or receptor-
mediated mechanisms or by non-saturable transmem-
brane or intercellular diffusion. Banks and colleagues
[10] first demonstrated that both PACAP27 and
PACAP38 could cross the BBB. Interestingly, the per-
meability for PACAP38 decreased as the concentration
of PACAP38 increased in the blood, which was not true
for PACAP27. Based on these initial observations au-
thors suggested that PACAP38 traversed the BBB via a
saturable mechanism, whereas the PACAP27 uptake
must be via a non-saturable mechanism [10]. Ki (influx
constant) for PACAP38 (2.86 μL/g/min) was slightly
higher than and PACAP27 (2.13 μL/g/min) although
PACAP38 is a larger and less lipid soluble molecule.
However, the percentage of intact iodine-labelled
PACAP27 (I-PACAP27) in the brain was 76.9% versus
58.9% for the PACAP38 [10]. Taken together, these
observations suggest efflux of PACAP27 from the brain
to blood via the saturable beta-F1 ATPase, which is
highly specific for PACAP27 [16]. Interestingly, the
passage of PACAP38 was not affected by a general
disruption of the BBB by lipopolysaccharide [15], but
after occlusion of the MCA [19].
Two human MR-angiography studies found no func-
tional effect of intravenously infused PACAP38 on the
MCA but a 17–19% and 2 h sustained dilation of the
middle meningeal artery (MMA) in healthy volunteers
[4] and migraine patients [5]. Interestingly in vitro
studies reported presence of PACAP receptors in the
meningeal as well as cerebral arteries [20, 21]. Thus,
the selective dilation of the MMA but not the MCA
may suggest that intravenously administrated PACAP38
most likely did not cross the BBB. Another human
study has shown that infusion of PACAP38 can induce
premonitory symptoms in 48% of patients with induced
attacks [22], which may be a central effect via the hypo-
thalamus [23]. However, PACAP38 infusion did not
induce more premonitory symptoms in patients who
developed an attack compared with those who did not
develop an attack, which suggest that induction of
premonitory symptoms is not a necessary mechanism
for the induction of migraine. Moreover, PACAP38-
induced migraine attacks are accompanied by change in
the intrinsic brain connectivity [24]. These observations
suggest either that there is a difference between species
or that the efflux mechanisms for PACAP38 work even
faster in man to transport PACAP38 from the endothe-
lial cells back to the blood. Thus, PACAP cannot exert
its effect although it can cross the BBB or enter the
endothelial cells. In contrast, Nonaka et al. [14] re-
ported the highest amount of iodine-labelled PACAP38
(I-PACAP38) in for instance the hypothalamus. Alter-
natively, the PTS-6 system may be limited to the capil-
lary endothelium and not the large arteries of the brain,
where the endothelium may work as a structural barrier
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denying access to PACAP38 from the blood to the
smooth muscle cell where the PACAP-receptors are
located. PACAP-receptors are found in the entire brain
and one study reported uptake of I-PACAP38 in all
brain regions after intranasal administration [17]. It
would be interesting to directly compare effect on the
central nervous system and cerebral arteries after intra-
venous and intranasal administration.
It has previously been speculated and suggested that
the BBB might be more permeable during migraine
attacks [25]. However, recent advanced MRI using intra-
venous gadolinium contrast performed during and
outside of attacks of migraine with [26] and without aura
[27] reported no significant change in the BBB perme-
ability. The clinical impact of determining whether intra-
venous PACAP has a CNS effect is related to the
potential of developing PACAP or PACAP receptor anti-
bodies as treatment. Currently, there is an ongoing
PAC1 receptor antibody trial for migraine treatment
(ClinicalTrials.gov Identifier: NCT03238781).
Conclusion
PACAP38 transport from the blood to brain and from
brain to blood is saturable carrier-mediated, whereas
PACAP27 crosses the BBB from the blood to brain by
transmembrane diffusion. The transport of PACAP27 the
brain to blood is mediated by a saturable and peptide-
carrier. There is no solid evidence yet of PACAP38 pass-
ing the BBB following exogenous infusion in migraine
models that can lead to brain function and brain vessel
changes, so it is possible that the PACAP migraine indu-
cing effect is caused by peripheral mechanisms, which
could be via inducing changes in the meninges or affecting
nociceptors in extracranial vessels both devoid of the BBB.
Future advanced in vivo human studies and exploration of
PAC1-receptor antibodies using radio-labelled tracers are
highly needed to clarify how and where PACAP may lead
to the development of migraine pain.
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